Filing Details

Accession Number:
0001209191-15-043030
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-05-14 21:24:20
Reporting Period:
2015-05-12
Filing Date:
2015-05-14
Accepted Time:
2015-05-14 21:24:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1339970 Atyr Pharma Inc LIFE Biological Products, (No Disgnostic Substances) (2836) 203435077
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1253170 Srinivas Akkaraju C/O Atyr Pharma, Inc.
3545 John Hopkins Court, Suite #250
San Diego CA 92121
Yes No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-05-12 1,546,126 $0.00 1,546,126 No 4 C Indirect By Sofinnova Venture Partners IX, L.P.
Common Stock Acquisiton 2015-05-12 320,000 $14.00 1,866,126 No 4 P Indirect By Sofinnova Venture Partners IX, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Sofinnova Venture Partners IX, L.P.
No 4 P Indirect By Sofinnova Venture Partners IX, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series E Redeemable Convertible Preferred Stock Disposition 2015-05-12 14,968,722 $0.00 1,546,126 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Person converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on a 1-for-9.6814 basis.
  2. Reflects a 1-for 9.6814 stock conversion of the Issuer's Preferred Stock into Common Stock which became effective immediately prior to the closing of the Issuer's initial public offering.
  3. The shares are owned by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., Dr. Srinivas Akkaraju, and Dr. Anand Mehra are managing members of SM IX and exercise shared voting and investment power with respect to the shares owned by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.